Monotherapy frequently fails to achieve satisfactory outcomes in solid tumors because of the complexity of the tumor microenvironment, which imposes adaptive and protective mechanisms on cancer cells. The authors frame multimodal collaborative therapy as a strategy to overcome these limitations by combining complementary mechanisms to increase tumor cell kill and bypass microenvironmental resistance.
The study describes a ZIF-90-based nanosystem—designated CP@ZIF-PQ/Ce6 NPs—engineered to co-deliver multiple functional components. The nanoparticle formulation incorporates: copper peroxide (CP) nanoparticles as a CDT and oxygen-generation agent, the autophagy inhibitor primaquine phosphate (PQ), and the photosensitizer chlorin e6 (Ce6). ZIF-90 serves as the metal–organic framework scaffold to encapsulate and stabilize these cargos within a single platform.
CP@ZIF-PQ/Ce6 NPs are intended to act through four coordinated mechanisms:
Photodynamic therapy (PDT): Ce6 enables light-activated generation of reactive oxygen species in the presence of oxygen.
Chemodynamic therapy (CDT): Copper peroxide is leveraged to catalyze in situ chemical reactions that produce cytotoxic species, contributing to oxidative stress within tumor cells.
Oxygen generation: Decomposition of copper peroxide within the nanoparticle can produce oxygen, which helps alleviate tumor hypoxia and thereby enhances oxygen-dependent PDT.
Autophagy inhibition: Primaquine phosphate is included to block autophagy-mediated protective pathways in tumor cells, preventing a survival mechanism that might otherwise mitigate therapy-induced damage.
The combined action of these mechanisms is designed to amplify reactive oxygen species (ROS) production and to interrupt cell-intrinsic defenses that limit the efficacy of monotherapies.
A key feature of the CP@ZIF-PQ/Ce6 nanosystem is its dual pH- and ATP-responsive behavior. The platform is engineered to release its payload preferentially in response to tumor-associated triggers—acidic pH and elevated ATP—thereby promoting drug liberation within the tumor microenvironment while limiting premature release in normal tissues. This responsiveness underpins the tumor-selective activation of PDT, CDT, oxygen generation, and autophagy inhibition.
In vitro studies reported by the authors demonstrate that CP@ZIF-PQ/Ce6 NPs increase intracellular ROS generation and counter tumor hypoxia under the experimental conditions described. The autophagy inhibitor component mitigates autophagy-related survival responses in tumor cells, enabling improved cytotoxic effects when PDT and CDT are applied together. Specific experimental parameters, quantitative results, and cell-line identities were reported in the full article but are not detailed in the abstract.
The nanosystem was evaluated in vivo and, according to the abstract, showed potent antitumor activity alongside favorable biocompatibility. These findings indicate that the integrated multimodal approach achieved enhanced tumor suppression in animal models while maintaining an acceptable safety profile in the contexts tested. The abstract notes use of in vivo models but does not provide numerical efficacy, dosing, or toxicity data; such methodological and quantitative details are reported in the full text.
The authors conclude that CP@ZIF-PQ/Ce6 NPs successfully integrate PDT, CDT, oxygen-generating therapy, and autophagy inhibition into a single, tumor-responsive platform. By enhancing ROS production, relieving hypoxia, and blocking autophagy-mediated protection, the nanosystem addresses several microenvironmental barriers that limit monotherapy. The study provides experimental evidence supporting multimodal cooperative antitumor therapy using a ZIF-90 metal–organic framework and highlights the potential of tumor-triggered, combination nanosystems to improve therapeutic outcomes in breast cancer models.
Note: The abstract summarizes the formulation strategy, proposed mechanisms, and reported in vitro and in vivo efficacy and biocompatibility. Specific experimental details, quantitative outcomes, and full methodological descriptions are contained in the full article and are not included in the abstract.